Key Insights• According to the research report, "France EPA & DHA Market Outlook, 2031," published by Actual Market Research, the France EPA & DHA Market is anticipated to grow at more than 6.62% CAGR from 2026 to 2031. The French EPA & DHA market is steadily expanding as the country faces an accelerating demographic aging profile and a significant burden of cardio-neurovascular disease, alongside a mature pharmacy-led food supplement culture. According to INSEE, France's population reached 69.1 million on January 1, 2026, with people aged 65 and older accounting for 22.2% of the population. In 2025, France recorded approximately 645,000 births and 651,000 deaths, the first year since 1945 in which deaths exceeded births, while the total fertility rate fell to 1.56 children per woman, the lowest level since the end of World War I. According to Santé publique France, cardio-neurovascular diseases caused around 140,000 adult deaths and approximately 1.2 million adult hospitalizations in 2022, accounting for more than one in five deaths. Ischemic heart disease alone led to more than 240,000 hospitalized patients and 31,000 deaths, while around 23% of adults have high LDL cholesterol and 31% have hypertension. The growing clinical burden is placing additional pressure on the French healthcare system and consumer health sector to strengthen access to EPA and DHA through supplements, fortified foods, infant nutrition, and clinical nutrition.• France's EPA & DHA market is characterized by a well-structured ecosystem comprising pharmacy and parapharmacy networks, French supplement laboratories, multinational consumer health companies, infant formula producers, and one of Europe's largest pet food industries.

Pharmacies remain the dominant and most trusted channel for food supplements, supported by pharmacist advice and the strong positioning of French brands such as Arkopharma, Nutergia, Pileje, and Nutrisanté. According to IQVIA, the French food supplement market across pharmacy, parapharmacy, e-pharmacy, and Amazon reached approximately EUR 2 billion in 2025, growing 4.7%, with online channels representing 8.3% of sales but contributing 28% of growth. France is also home to omega-3 ingredient producer Polaris in Brittany, major infant formula manufacturers such as Lactalis and Danone, and the global headquarters of Royal Canin in the south of France.• Regulatory oversight for EPA and DHA products in France is shaped by European Union legislation implemented and enforced nationally. Food supplements are regulated under Directive 2002/46/EC, transposed through Decree No. 2006-352, and must be declared to the Directorate General for Competition, Consumer Affairs and Fraud Control (DGCCRF) before marketing. The French Agency for Food, Environmental and Occupational Health and Safety (ANSES) provides nutritional references and operates the national nutrivigilance system. Health claims are governed by Regulation (EC) No. 1924/2006 and Regulation (EU) No. 432/2012, infant formula must contain DHA at 20–50 mg per 100 kcal under Delegated Regulation (EU) 2016/127, and algal and krill oils require EU Novel Food authorization.

In March 2025, France adopted the updated Nutri-Score algorithm through an arrêté dated March 14, 2025, which revised calculation rules to better reflect nutritional guidance, including for fats and oils.Market Outlook• A defining characteristic of France's EPA & DHA market is the central role of the pharmacist and the premium positioning of omega-3 within the broader supplement category. French consumers favor products with strong scientific credentials, clear dosing, and French or European manufacturing, which supports pharmacy-exclusive brands offering high-concentration fish oils, krill oil, and algal DHA. IQVIA's analysis shows that product launches and renovations generated EUR 96 million of additional sales in 2025, offsetting negative volumes on existing products, highlighting the importance of innovation in formats such as smaller capsules, liquid omega-3s, and combination products for cognitive, cardiovascular, and eye health. Simultaneously, e-pharmacies and Amazon are emerging as key growth drivers, with Amazon supplement sales growing 19% in 2025.• The market also reflects France's growing emphasis on prevention and healthy aging. Santé publique France's March 2025 report on cardio-neurovascular disease highlighted persistent social and gender inequalities, with stroke causing around 18,000 deaths among women each year and being the leading cause of cardiovascular death in women, while 45% of people with hypertension remain unaware of their condition. The updated Nutri-Score algorithm adopted in March 2025 is encouraging food manufacturers to improve the nutritional profile of their products, creating opportunities for omega-3-rich foods and oils.

In infant nutrition, births declined 2.1% to approximately 645,000 in 2025, constraining formula volumes, although the mandatory DHA requirement ensures a stable baseline of demand for high-purity fish and algal DHA.Market DynamicsDriver: Demographic aging and cardio-neurovascular disease burden supported by pharmacy-led supplement cultureFrance's EPA & DHA market is primarily driven by demographic aging and the substantial burden of cardio-neurovascular disease. People aged 65 and older represented 22.2% of the population on January 1, 2026, according to INSEE, and France recorded more deaths than births in 2025 for the first time since 1945. Cardio-neurovascular diseases caused around 140,000 adult deaths and 1.2 million hospitalizations in 2022, according to Santé publique France, with 23% of adults having high LDL cholesterol. Pharmacists play a central role in recommending omega-3 supplements for cardiovascular, cognitive, eye, and joint health, while EU-authorized health claims allow EPA and DHA products to communicate benefits for normal heart function, blood triglyceride levels, and, for DHA, normal brain function and vision. As awareness of prevention and healthy aging continues to grow, pharmacies and e-pharmacies are witnessing sustained demand for EPA and DHA products.Challenge: Volume pressure, raw material volatility, and strict regulatory scrutiny of claimsOne of the principal challenges facing France's EPA & DHA market is weak underlying volume growth for established products, with IQVIA reporting negative volumes of EUR 35 million on existing products in 2025, making growth increasingly dependent on innovation and price. At the same time, raw material costs remain volatile.

Peru's first 2026 north-central anchovy quota was set at 1,914,049 tonnes, approximately 36% lower than in 2025, following a coastal El Niño event, while the Antarctic krill fishery closed early on August 1, 2025, and again on August 12, 2026. Additionally, the DGCCRF actively monitors supplement labelling and claims compliance, and ANSES's nutrivigilance system can lead to recommendations restricting certain ingredients or uses. Together, these factors require continuous investment in compliance, scientific substantiation, and product differentiation.Trend: Digital channel growth, naturalness, and expansion of algal and sustainable omega-3France is experiencing a significant shift toward digital purchasing and natural, sustainable omega-3 solutions. Online channels contributed 28% of supplement market growth in 2025, up from 13% in 2024, as consumers increasingly purchase from e-pharmacies and marketplaces. French consumers' preference for naturalness and traceability is supporting demand for wild-caught, sustainably certified fish oils and fish-free algal oils, with ingredient innovation such as dsm-firmenich's life'sDHA B54-0100, launched in October 2024 with 545 mg DHA and 80 mg EPA per gram, enabling more compact capsules. The continued expansion of EU-authorized algal oils, including Schizochytrium sp. (CABIO-A-2) oil authorized in July 2024, is broadening supply options for formula and supplement manufacturers.

The growing emphasis on cognitive health among seniors and on prenatal nutrition is also boosting demand for DHA-rich products.Policies• Food Supplement Declaration (Decree No. 2006-352): Food supplements containing EPA and DHA are regulated under Directive 2002/46/EC and Decree No. 2006-352. Products must be declared to the DGCCRF through its online declaration platform before marketing, and must comply with composition, labelling, and safety requirements enforced by the DGCCRF.• EU Nutrition and Health Claims Regulation: Health claims for EPA and DHA are governed by Regulation (EC) No. 1924/2006 and Regulation (EU) No. 432/2012, authorizing claims for normal heart function, blood triglyceride levels, blood pressure, and DHA contributions to normal brain function, vision, and maternal and infant development, subject to specified intake conditions.• Infant Formula DHA Requirement: Under Delegated Regulation (EU) 2016/127, infant formula and follow-on formula must contain DHA at 20–50 mg per 100 kcal, ensuring stable demand for high-purity fish and algal DHA among French formula manufacturers.• ANSES Nutrivigilance and Nutritional References: ANSES operates the national nutrivigilance system for monitoring adverse effects associated with food supplements and fortified foods, and establishes nutritional references for omega-3 fatty acids that inform public health guidance and product formulation.• Nutri-Score and Novel Food Authorization: The updated Nutri-Score algorithm, adopted through the arrêté of March 14, 2025, revised calculation rules for packaged foods, influencing the positioning of omega-3-rich foods and oils. Krill oil and algal oils require authorization under Regulation (EU) 2015/2283 and listing in the Union list of novel foods.Segment AnalysisFrance EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within France, particularly in infant formula, prenatal supplements, and cognitive and eye health products for seniors. DHA is mandatory in infant formula, and algal DHA is increasingly used in prenatal and vegetarian ranges.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in France, driven by increasing interest in high-EPA concentrates for cardiovascular health, mood support, and inflammation-related wellness.France EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in France due to its cost-effectiveness and broad consumer familiarity, with French producers such as Polaris supplying refined and concentrated omega-3 oils.• Algae Oil represents the fastest-growing source category in France, driven by infant formula use, vegetarian demand, and consumer preference for sustainable and contaminant-free sources.• Krill Oil is a premium source category positioned for absorption and smaller capsule size, sold primarily through pharmacies and online channels.• Other Marine Sources hold a niche position in the French market, including cod liver oil, salmon oil, and marine phospholipids, primarily used in specialty supplements and pet nutrition.France EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in France, within a supplement market of approximately EUR 2 billion in 2025 according to IQVIA, distributed primarily through pharmacies, parapharmacies, and e-pharmacies.• Infant Formula represents a strategically important application segment, with DHA mandatory in all infant and follow-on formulas. France is also a major formula producer and exporter through companies such as Lactalis and Danone.• Pharmaceuticals represent an important application segment, including prescription omega-3-acid ethyl esters for hypertriglyceridemia and pharmaceutical-grade omega-3 ingredients.• Food & Beverages encompasses omega-3-enriched oils, spreads, eggs, dairy, and bread, with reformulation encouraged by the updated Nutri-Score.• Clinical Nutrition & Medical Foods includes fish oil-based lipid emulsions for parenteral nutrition and enteral formulas used in hospitals and home care.• Pet Nutrition represents the fastest-growing application segment in France, supported by a pet population of approximately 75.1 million in 2024, including 16.7 million cats and 9.7 million dogs, with 61% of households owning a pet, according to FACCO.Major EPA & DHA Manufacturers Operating in France• Polaris, dsm-firmenich, KD Pharma Group, Arkopharma, Pileje, Nutergia, Pierre Fabre, Lactalis, Danone, Nestlé, Royal Canin (Mars), Fresenius Kabi, and Aker BioMarine are leading players in the French EPA & DHA market, offering refined and concentrated omega-3 oils, finished supplements, DHA-fortified infant formula, pet foods, and clinical nutrition products. Their strong presence, pharmacy partnerships, scientific support programs, and relationships with healthcare professionals have driven adoption across the French market.• The market is also supported by contract manufacturers, private-label producers, ingredient distributors, and testing laboratories that provide formulation, encapsulation, and quality assurance support.

With strong domestic formula and pet food manufacturing and a pharmacy-led supplement culture, France remains one of Europe's most important omega-3 markets.France EPA & DHA Supply and Pricing Economics• EPA and DHA products in France represent value-added nutritional products whose pricing depends on source, concentration, chemical form, certification, and channel. Pricing varies considerably between pharmacy brands, supermarket products, krill oil, and algal oil.• Refined fish oil prices normalized by late 2024 after the El Niño-related disruption, according to GOED, but the reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on raw material prices.• Supplements are paid out-of-pocket, with some complementary health insurers (mutuelles) offering partial reimbursement of prevention products. Prescription omega-3 medicines are reimbursed by the national health insurance only for approved indications.• Algal oil and krill oil command a premium over standard fish oil, while online channels and Amazon are intensifying price competition.Market Outlook by Consumer Health Spending and Supply Infrastructure• France's EPA & DHA market growth is strongly linked to demographic aging, consumer health spending, and the strength of the pharmacy channel, although weak underlying volumes and raw material volatility remain significant factors influencing growth.• Private consumer spending drives the supplement and pet nutrition segments, while the mandatory DHA requirement in infant formula and France's role as a formula exporter provide a stable demand base. E-pharmacies and marketplaces are expanding access to premium formats.• The future growth opportunity for EPA and DHA in France depends on sustained innovation, digital channel growth, consumer education on cardiovascular and cognitive health, and continued expansion of sustainable and algal omega-3. Greater integration of pharmacist-led prevention advice and healthy aging programs will likely become key strategies for expanding category penetration.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.